Nanosilver-based antibacterial drugs and devices: mechanisms, methodological drawbacks, and guidelines

Area of Science:

• Nanotechnology
• Materials Science
• Infectious Diseases

Background:

• Bacterial infections pose a significant global health threat, exacerbated by microbial resistance and declining antibiotic development.
• Pharmaceutical companies are shifting investments away from antibiotics, necessitating novel antibacterial strategies.
• Nanotechnology, specifically silver nanoparticles (AgNPs), presents a promising, cost-effective alternative for antibacterial applications.

Purpose of the Study:

• To review the current understanding of silver nanoparticle (AgNP) antibacterial effects and mechanisms.
• To discuss challenges and limitations in AgNP research, including standardization and toxicity assessment.
• To propose strategies for developing effective AgNP-based antibacterial drugs and devices.

Main Methods:

• Comprehensive analysis of experimental data on the bactericidal effects of silver nanoparticles (AgNPs).
• In-depth examination of the molecular mechanisms underlying AgNP-bacteria interactions and toxicity.
• Review of existing methods for antibacterial testing of AgNPs and identification of limitations.

Main Results:

• Silver nanoparticles (AgNPs) exhibit broad-spectrum antibacterial and antiviral properties with cost-effective synthesis.
• Key challenges include understanding AgNP-bacteria interaction mechanisms, defining toxicity parameters, and standardizing testing methods.
• Existing research highlights the potential of AgNPs but also points to a need for refined strategies and guidelines.

Conclusions:

• Silver nanoparticles (AgNPs) are a viable option for developing new antibacterial agents and combating antimicrobial resistance.
• Further research is needed to elucidate molecular mechanisms, standardize testing, and establish clear design principles for AgNP-based antibacterial systems.
• Standardized protocols and clear guidelines are essential for the safe and effective development of nanosilver-based antibacterial drugs and devices.